MSDC-0602 是一种 PPARγ 保留的噻唑烷二酮类药物 (TZD)，与线粒体丙酮酸载体 (MPC) 相互作用并抑制其活性，对治疗 2 型糖尿病有效，且降低 pparγ 介导的副作用的风险。
CAS：1133819-87-0
分子式：C19H17NO5S
分子量：371.41
纯度：98%
存储：Store at -20°C

Background:

MSDC-0602, a PPARγ-sparing thiazolidinedione (TZD), interacts with the mitochondrial pyruvate carrier (MPC) and inhibits its activity and are effective for treatment of type 2 diabetes with reducing risk of PPARγ-mediated side effects[1][2].

[1]. Chen Z, et al. Resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. [2]. Vigueira PA, et al. The beneficial metabolic effects of sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol. 2017 Aug 1;102(8):985-999.